Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The use of adeno-associated virus (AAV) as a gene therapy vector has been approved recently for clinical use and has demonstrated efficacy in a growing number of clinical trials. However, the safety of AAV as a vector has been challenged by a single study that documented hepatocellular carcinoma (HCC) after AAV gene delivery in mice. Most studies have not noted genotoxicity following AAV-mediated gene delivery; therefore, the possibility that there is an association between AAV and HCC is controversial. Here, we performed a comprehensive study of HCC in a large number of mice following therapeutic AAV gene delivery. Using a sensitive high-throughput integration site-capture technique and global expressional analysis, we found that AAV integration into the RNA imprinted and accumulated in nucleus (Rian) locus, and the resulting overexpression of proximal microRNAs and retrotransposon-like 1 (Rtl1) were associated with HCC. In addition, we demonstrated that the AAV vector dose, enhancer/promoter selection, and the timing of gene delivery are all critical factors for determining HCC incidence after AAV gene delivery. Together, our results define aspects of AAV-mediated gene therapy that influence genotoxicity and suggest that these features should be considered for design of both safer AAV vectors and gene therapy studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“preclinical data suggest AAV integration events occur in a dose-dependent manner with a preference for integration at sites of active transcription, tissue-specific promoters are protective against oncogenesis.178, 179, 180”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [179]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“GCGCGCTCGCTCG-3′) were trimmed by cutadapt (57).”
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“To investigate this possibility, we developed a vector, AAV8-hAAT-synMUT, modeled on a AAV vector that had been administered to human subjects with hemophilia and did not cause genotoxicity in mice (13, 33).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In fact, there are multiple human AAV gene therapy trials around the world that have been completed, are accruing participants, or are in preparation (4), and recent studies using AAV to treat 3 genetic disorders have been regarded as successful (5–8).”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“The most relevant example is the failure of animal studies to predict the increased risk for the development of leukemia after retroviral gene therapy for X-linked severe combined immunity deficiency (45).”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 2×
“…the use of a more hepatotrophic serotype, such as AAV8 compared with AAV2, led to an increase in the rate of HCC. Additionally, the use of distinct capsids to pseudotype AAV vectors (48), such as serotypes 8 and 9, confers distinct patterns of tissue troph-ism in wild-type and disease states (49).”
Research works printed but not linked: 1
- Martin, 2011, EMBnetJ., 17
Cited by
Items 401–422 of 422
Bella, T. L. (2018) · theses.fr (ABES) · doi:10.70675/e88d9a08za929z4c0fzb8d9z9f01cd69ca39
Développement de nouvelles stratégies de thérapie génique pour le syndrome de Leigh
Reynaud-Dulaurier, R. (2022) · theses.fr (ABES) · doi:10.70675/b7b02210za175z491eza3dbzb67e5d705506
Gardin, A. (2023) · theses.fr (ABES) · doi:10.70675/ac839ccez52b2z45bez9294ze72731823d9b · Cited by 1
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Systemic delivery of AAV-GFM1 corrects COXPD1 molecular alterations in Gfm1R671C/− mice
Molina‐Berenguer, M., Herrero-Martínez, D., Vallbona-Garcia, A., Vila‐Julià, F., Cámara, Y., Vales, Á., González‐Aseguinolaza, G., Torres‐Torronteras, J., & Martí, R. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00426-4 · Cited by 1
“…and AAV9P31-hSyn-GFM1 vectors was not associated to body or tissue alterations in KI/KO mice supports the safety of the treatment, which is relevant as some deleterious effects associated with AAV-mediated therapies have been observed in other studies (Chandler et al, 2015; Donsante et al, 2007).”
Liu, B., Klatt, D., Harris, C. E., McGuinness, M. K., Brendel, C., & Williams, D. A. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag500
Chen, X., Xie, Q., Nath, S. J., Tang, M., Ma, H., Günes, Y. Ö., Sharma, T., Liu, H., Cui, M., Du, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73545-8
“AAVvector integrationwiththe CMVen / CB promoteralterstheexpressionlevelsof several miRNAs encoded in the Rian locus and adjacent genes, leading to the development of HCC 41,56,79 .”
InfluentialRamamurthy, R. M., Zheng, W. T., Wachtman, S. E., Diaz, J. H., George, S. K., Simon, T., Zhou, Y., Wan, M., Lu, B., Walker, S. J., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201772
“16 By contrast, a 10-year follow-up of AAV-mediated FVIII expression in adult HA dogs also detected >1,700 integration events and clonal expansion in liver tissue, but there was no evidence of tumorigenesis.”
“Just right” AAV gene therapy for spinal muscular atrophy
Chen, X., & Xie, J. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.022
Critical Appraisal of the Integrin αV–YAP–CTGF Axis in Congestive Hepatopathy
Sun, J., Guan, Z., & Liu, Y. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.04.044
The Role of MicroRNAs in the Onset and Progression of Alzheimer’s Disease: An Explicative Overview
Sarkar, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010009
abdelnaby, M., Galiakberova, A. A., & Dashinimaev, E. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156846
“Although rAAV genomes persist predominantly as episomal concatemers, integration into the host genome does occur and has been associated with hepatocellular carcinoma in multiple animal models [104,105].”
Coratella, E., Lemmens, M., Oertli, M., Gilbart, Y., Davidsen, K., Bontadelli, L., Bohnert, R., Rigal, J., Bian, J., Alpert, T., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103050
Cai, S. S., Slater, C. L., Farag, V., Gonzalez, G., Yang, V., Patel, M., Qi, A., Huerta, V., Cheng, L., Zhu, Y., et al. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103514
Hepatotoxicity in Adeno-Associated Virus Gene Therapy: Clinical Challenges and Strategic Solutions
Asai, A., Aqul, A. A., Banc‐Husu, A. M., Diamond, T., Elisofon, S. A., Freeman, A. J., Loomes, K. M., Mohammad, S., Sundaram, S. S., & Chapin, C. A. (2026) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2026.115317
Electroporation-Mediated Delivery of CRISPR Technologies for Liver Disease Cell Therapy and Modeling
Cottle, R. N. (2026) · Springer eBooks · doi:10.1007/978-3-319-26779-1_289-1
Cascino, F. (2023) · Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele
Cell type specific gene delivery using chemically modified AAV vectors
Barenghi, A. (2022) · SDL
HEAT SHOCK PROTEIN 70 INDUCIBLE GENE EXPRESSION AS AN ALTERNATIVE TO TET-SYSTEM IN HEK293 CELLS
Banuelos, A. C. (2026) · Library, Museums and Press - UDSpace (University of Delaware)
CNS targeted AAV gene therapies: Recent advances and clinical insights
Brown, B. P., Lewis, R. W., Jr., & Davidson, B. L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103118
Metadata
- Authors
- Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., & Venditti, C. P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-01-20
- Volume
- 125
- Issue
- 2
- Pages
- 870-880
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4319425
- OpenAlex
- W2133112334
- Cited by
- 403
- References
- 63
- Citations by year
- 2026: 28 · 2025: 42 · 2024: 40 · 2023: 38 · 2022: 36 · 2021: 32 · 2020: 45 · 2019: 30 · 2018: 26 · 2017: 32 · 2016: 31 · 2015: 22
- FWCI
- 25.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- adeno-associated virus, gene therapy vectors, hepatocellular carcinoma, genotoxicity, AAV integration, microRNA overexpression, RTL1, vector dose
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Mutant Strains, Pregnancy Proteins, Transduction, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.